UNSPSC 51392205: Detomidine

This classification denotes an alpha-adrenergic agonist with the molecular formula C12H14N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7N8K34P2XH, chemically known as 4-(2,3-dimethylbenzyl)imidazole but generally known as detomidine, which bears US NIH Compound Identifier 56032. European Medicines Agency schedules Detomidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07012MIG. The term DETOMIDINE is an International Non-Proprietary Name.

UNSPSC 51392205 Detomidine is a Commodity code that in recent state and local procurement reflects pharmaceutical and health-services acquisition — specifically naloxone and drug deactivation systems sourced for community health and public-health emergency response. The code captures purchases by health authorities and county public-health departments seeking to stock controlled substances, overdose-reversal medications, and related medical supplies for distribution and emergency use. Issuing bodies include county health departments and state health and human services agencies conducting competitive procurements for pharmaceutical inventory, with a mix of community-health-focused IFB solicitations and exploratory RFI vehicles used by state-level agencies to assess vendor capabilities before formal purchasing.

Activity is concentrated in Florida and Texas based on recent postings. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries to its Community Health Building in Sanford, with a response deadline of July 26, 2023, and a two-year initial contract term plus one-year renewal option on a fixed-fee basis. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to gather vendor intelligence on direct-to-manufacturer prescription programs and therapeutic pharmacy initiatives, reflecting state-level interest in restructuring pharmaceutical procurement outside traditional pharmacy benefit manager and group purchasing organization channels. Neither opportunity specifies set-aside designations; both require E-Verify compliance, drug-free workplace certification, and standard insurance coverage (workers' compensation, general liability, professional liability).